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Abstract
Context—Androgen deprivation therapy (ADT) is widely used to manage the symptoms of
advanced prostate cancer and has been shown to slow the progression of the disease. Previous
research investigating racial differences in the use of ADT has reported inconsistent findings.
Objectives—The purpose of this study was to assess use trends for ADT overall and by type
(orchiectomy and luteinizing hormone-releasing hormone [LHRH] agonists) and the factors
associated with time to receipt for metastatic prostate cancer.
Methods—Data from the Surveillance, Epidemiology, and End Results (SEER) cancer registry
and Medicare claims database were obtained for 5,273 men, aged 65 years and older and
diagnosed with Stage IV prostate cancer during 1991–1999 from seven SEER regions. An
accelerated failure time regression model with lognormal distribution was used to examine factors
associated with mean time to receipt of ADT.
Results—African-American men were less likely than white men to receive any ADT after
diagnosis (P < 0.001). Differences were noted in the time to receipt of ADT, with African-
American men having a longer mean time to receipt of orchiectomy (time ratio [TR] = 1.50; 95%
confidence interval [CI] = 1.03, 2.17) or LHRH agonist (TR = 1.42; 95% CI = 1.06, 1.89) than
white men.
Conclusion—African-American men with metastatic prostate cancer were significantly less
likely to receive ADT and, when treated, had a slightly longer time to receipt than white men,
which has implications for patients and physicians involved in the palliative management of
metastatic prostate cancer.
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The incidence and mortality rates for prostate cancer have gradually declined in the United
States since 1993.1,2 However, African-American men still have prostate cancer incidence
and mortality rates that are acutely higher than those of men from any other racial and ethnic
background.2 Several factors have been posited as possible contributors to the racial
disparity in prostate cancer incidence and mortality, including the presentation of more
African-American men with advanced disease at diagnosis.2,3 Although fewer than 5% of
prostate cancer diagnoses are made when the disease has metastasized to other parts of the
body, African-American men are more often diagnosed at this advanced stage and have a
lower five-year relative survival rate compared with white men diagnosed at this stage.4,5
A curative therapy for metastatic prostate cancer does not exist, although the efficacy of
androgen deprivation therapy (ADT) for the palliative management of advanced prostate
cancer symptoms was first reported more than 65 years ago and continues to be the standard
treatment.6,7 The use of ADT has increased over time for prostate cancer,8,9 even as the
incidence of prostate cancer has declined, and as the initial therapeutic modality, bilateral
orchiectomy, has been supplanted by luteinizing hormone-releasing hormone (LHRH)
agonists that were introduced in 1982.7,10 The two modalities of ADT have comparable side
effects, although there are added surgical risks associated with orchiectomy and added time
commitments and cost associated with repeated administrations of LHRH agonists. Previous
research investigating racial differences in the use of ADT have reported inconsistent
findings of both no racial differences2,11,12 and significant racial differences13,14 as well as
reports that ADT is less likely to be discussed as a treatment option with African-American
men than white men.11
Previous studies of prostate cancer treatment have reported that African-American men with
localized prostate cancer have a longer median time between diagnosis and a subsequent
medical visit or procedure and receive less medical monitoring than white men.15 Although
the most appropriate time to administer ADT to men with metastatic prostate cancer is
undetermined,16 underuse or delays in initiation of ADT may affect quality of life and/or
survival, because ADT is widely used to manage the symptoms of advanced prostate cancer
and has been shown to slow the progression of the disease.17,18 Previous studies have not
investigated racial differences in the use of ADT modalities and time to receipt of ADT, and
the purpose of this study was to evaluate trends and racial differences in the use and time to
receipt of ADT among men with metastatic prostate cancer, with a goal of informing and
improving future clinical management of this population.
Methods
This study used data from the Surveillance, Epidemiology, and End Results (SEER)-
Medicare Linked Data base. An overview of the SEER-Medicare data has been previously
published.19 Briefly, the SEER Program collects population-based cancer registry data
consisting of demographics, tumor site, tumor morphology, stage at diagnosis, and treatment
for incident cancer cases from state or regional SEER cancer registries. The SEER data are
linked to beneficiary claims data from Medicare, which is the primary health insurance
program for adults 65 years of age and older and covers more than 97% of the U.S.
population.
The study sample included men with a primary diagnosis of prostate cancer during 1991–
1999, who were not first diagnosed at autopsy or by death certificate, had no other cancer
diagnoses, were aged 65 years and older, and had Medicare coverage (n = 127,056).
Participants were excluded if they were not diagnosed with American Joint Committee on
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Cancer modified Stage IV prostate cancer (n = 114,710), did not have complete claims (n =
3,618), received other types of hormonal therapies (n = 31), had a treatment date beyond 30
days before diagnosis (n = 85), multiple treatments occurring on same date (n = 2), or were
missing a diagnosis date (n = 65). Because this study focused on racial differences in
treatment, participants who were not African American or white (n = 510) were excluded,
and this study was limited to seven SEER sites (Atlanta, Connecticut, Detroit, Los Angeles,
San Francisco-Oakland, Seattle-Puget Sound, and San Jose-Monterey), resulting in a final
study sample size of 5,273.
Demographic characteristics (age, race, marital status, SEER region), diagnosis year, and
histologic grade were obtained from the SEER data. Histologic grade was determined
according to Gleason scores: well differentiated (Gleason score: 2–4), moderately
differentiated (Gleason score: 5–7), and poorly differentiated (Gleason score: 8–10).
Medicare claims were available for 1991–2002 and were used to create a comorbidity index
using inpatient and outpatient data.20 Claims data also were used to identify neighborhood
socioeconomic status (percent high-school education and household median income) at the
census tract level using the participant’s residential address, and to identify claims for
orchiectomies and LHRH agonists using the Healthcare Common Procedure Coding
System/Current Procedural Terminology (HCPCS/CPT) and International Classification of
Diseases, ninth revision, Clinical Modification (ICD-9-CM). Orchiectomy procedures were
identified using HCPCS/CPT codes 54520, 54521, and 54530, and ICD-9-CM codes 62.3,
62.41, and 62.42. The LHRH agonists evaluated were goserelin acetate and leuprolide
acetate, identified using HCPCS/CPT codes J9202, J9217, J9218, and J9219. Claims data
were available for years 1991 through 2002 for men diagnosed with prostate cancer between
1991 and 1999.
To assess group differences in ADT use, analysis of variance and linear regression were
used. The proportional hazards assumption for Cox regression was violated; hence, a time-
to-event analysis was done using accelerated failure time (AFT) regression models to
examine factors associated with time to receipt of ADT.21 AFT models are parametric
regression models similar to linear regression, which allow for modeling of censored data.
To select the best distribution for modeling our data, several functions were tested, and the
distribution with the best fit (the log normal) was selected. Use of the log normal allows us
to model the logarithm of the event time; hence, results are reported as estimates of the
expected time ratio (TR). Estimates less than 1 suggest comparatively shorter time to receipt
of ADT, and estimates greater than 1 suggest comparatively longer time to receipt of ADT.
Time to receipt of ADT was evaluated using three subsets of the original study population
based on ADT use: 1) orchiectomy vs. no ADT, 2) LHRH agonist vs. no ADT, and 3)
LHRH agonist vs. orchiectomy. In addition to the comparisons with men who received no
ADT, time to receipt of LHRH agonist vs. orchiectomy was examined to determine if there
were differences in time to receipt of the two modalities between African-American and
white men who received ADT. Variables included in the analyses were age, race, marital
status, diagnosis year, comorbidities, histologic grade, and SEER region. Neighborhood
socioeconomic status variables were evaluated in supplemental analyses but were not
included in final models, because the magnitude of the effect estimates were not appreciably
affected, and their inclusion resulted in collinearity issues and greater missing data.
Observations were censored at death or the end of the surveillance period (December 2002).
Minimum follow-up time was three years. All analyses were done using SAS Version 9.1
(SAS Institute, Cary, NC).
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The characteristics of study participants are presented in Table 1 by race. Most of the
participants were white (79%). African-American participants tended to be younger, not
married, have more comorbidities, and be resident in census tracts with lower high-school
education levels and median income. The mean time to receipt of any ADT was slightly
higher for African-American men (6.2 months) compared with white men (5.7 months),
although this difference was not statistically significant (P= 0.395).
Table 2 presents the characteristics of participants by ADT receipt. Overall, 28.3% did not
receive any ADT, 29% received an orchiectomy, and 42.7% received an LHRH agonist. A
greater proportion of African-American men did not receive ADT (38.8%) compared with
white men (25.5%) (P < 0.001). A smaller proportion of men aged 80 years and older
received an LHRH agonist (35.3%) than those of younger age groups (P < 0.001). Men with
no comorbidities were more likely to receive an LHRH agonist (47.4%), whereas men with
three or more comorbidities were more likely to have neither type of ADT (37.9%).
Figure 1 presents the proportion of participants who received orchiectomy, LHRH agonists,
or no ADT by year of diagnosis. Overall, the use of orchiectomy declined and the use of
LHRH agonists increased during the study period from 1991 to 1999. The proportion of
participants that did not receive ADT remained relatively stable throughout the period.
African-American men were less likely than white men to receive any ADT after diagnosis
(P < 0.001), and this racial difference persisted as the months since diagnosis increased (Fig.
2). When evaluating the modality of ADT used among men who received treatment, the
proportion of men receiving an LHRH agonist increased over time for African-American
and white men and was not significantly different by race (P = 0.117), although in the latter
years of the study period, African-American men lagged behind white men in both the
adoption of LHRH agonists and the concomitant decrease in orchiectomy (Fig. 3).
Table 3 presents the results of an AFT regression model to determine factors associated with
the time to receipt of ADT. In analyses adjusted for age, marital status, diagnosis year,
SEER region, histologic grade, and comorbidities, African-American men had a longer
mean time to receipt than white men for both orchiectomy (TR = 1.50; 95% confidence
interval [CI] = 1.03, 2.17) and LHRH agonist (TR = 1.42; 95% CI = 1.06, 1.89), using no
ADT as the reference group. When evaluating the use of an LHRH agonist vs. orchiectomy
among men who received ADT, African-American men had a 19% longer mean time to
receipt of the newer ADT modality than white men, although this association was not
statistically significant (TR = 1.19; 95% CI = 0.97, 1.45). Participants aged 80 years and
older had a shorter mean time to receipt than those aged 65–69 years for an orchiectomy
(TR = 0.13; 95% CI = 0.09, 0.20) or an LHRH agonist (TR = 0.47; 95% CI = 0.34, 0.64)
compared with no ADT. Furthermore, those with poorly differentiated disease had a shorter
mean time to receipt of an orchiectomy (TR = 0.26; 95% CI = 0.12, 0.54) or an LHRH
agonist (TR = 0.48; 95% CI = 0.28, 0.83) than those with well-differentiated disease, though
there was no statistically significant difference when comparing the newer and older
modalities.
Additional adjustment for neighborhood education and income did not significantly alter
these findings and were not included in the final analysis, because there was greater missing
data for these covariates, and their inclusion did not appreciably change the results.
Sensitivity analyses were done to evaluate the effect of censoring bias using a closed three-
year window instead of the open-study window, which could range from 3 to 10 years for
participants. The effect estimates were not appreciably altered; hence, only the results for the
entire study period are presented.
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Racial differences in the use of any ADT were noted in this study of elderly men diagnosed
with metastatic prostate cancer. African-American men were less likely to receive any ADT
and had a longer mean time to receipt of orchiectomy and LHRH agonists than white men.
Previous studies evaluating localized or regional prostate cancer12 and all stages of prostate
cancer22 have reported comparable use of ADT by whites and African Americans, but these
findings may have been the result of the multiple treatment options available for the earlier
stages of prostate cancer. In contrast, our study included only metastatic prostate cancer
cases, because ADT has been the primary therapy for advanced prostate cancer for decades.
Lesser adoption of LHRH agonists occurred during the latter years of the study period
among African-American men than white men. The relative utilization curves for LHRH
agonists and orchiectomy began to diverge around 1996, when, among those who used
ADT, a greater proportion of white men used LHRH agonists than African-American men,
and a greater proportion of African-American men used orchiectomy than white men. These
trends are notable, given innovation diffusion theory that posits that population adoption
over time follows an S-shaped curve where adoption increases (represented by an upward
slope in the curve) until a saturation inflection point is reached where adoption slows or
stops (represented by a flattening of the curve).23 The adoption of LHRH agonists in this
study resembles such an S-shaped diffusion curve (Fig. 3), except for the differential
adoption of LHRH agonists at the end of the curve (the later years of the study period).
Equity in the use of LHRH agonists would be expected during this time, because the
proportion of men treated reached saturation, but instead, a racial disparity in LHRH
adoption occurred.
The racial differences in mean time to receipt were small, but the overall range in time to
receipt was wide during the study period. This could be relevant, given the debate about the
most appropriate time to administer ADT for metastatic prostate cancer. The advantages and
disadvantages of early or deferred ADT and the factors that should determine the time
window, that is, prostate-specific antigen levels or time since diagnosis, have not been
clearly defined.24 Results from early studies by the Veterans’ Administration Cooperative
Research Group suggested that ADTshould be deferred until the presentation of
symptoms,25,26 whereas a later study reported that early receipt of ADT slowed the
progression of prostate cancer and associated pain.17 Recently, in its updated clinical
practice guidelines, the American Society of Clinical Oncology did not recommend the early
use of ADT because of results from a meta-analysis, which found no overall survival
advantage for the use of early ADT.27 Although there is still debate about the advantages
and disadvantages of early ADT, African-American men were less likely than white men to
receive this therapy and had a slightly longer mean time to receipt.
Previous studies have reported that orchiectomy and LHRH agonists have comparable
efficacies for the management of metastatic prostate cancer, with no differences in endocrine
responses, side effects, and survival.28,29 Thus, the decision to use ADT at all or one
modality of ADT instead of the other is probably influenced by a host of other factors, such
as personal preference, physician recommendations, or possibly, a combination of these
factors characterizing differential access, among other factors. Although this study did not
investigate factors associated with the use of a particular type of ADT, a previous study
reported that patients primarily selected orchiectomy for convenience and LHRH agonists to
avoid surgery.30 These findings suggest that selection of a particular type of ADT was
probably not influenced by possible side effects, because the side effects for both therapies
are comparable;31 however, the side effects may have been a factor for more than a quarter
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of our study population who did not receive any form of ADT and possibly among those
with more comorbidities, for whom comprehensive medical management may have been
more challenging.
Another potential limitation of our study is that the receipt of ADT was determined solely by
Medicare claims data. This probably did not affect our finding of a racial difference in ADT
receipt, because this would suggest that claim errors were disproportionately distributed by
the race of the patient, which is unlikely. There is a possibility that some claims may not
have been filed or may have been misfiled, although this is also unlikely to be a major
source of error, because a claim is necessary to receive reimbursement for medical services
rendered.32 In addition, the use of diethylstilbesterol (DES), an oral synthetic estrogen,
could not be evaluated in this study, because it is not reimbursed by Medicare. The use of
DES has declined over the years because of cardiovascular-related complications, but there
is a possibility that some men may have elected to pay the out-of-pocket costs associated
with receiving this alternative treatment and were incorrectly identified as not receiving
hormonal therapy for metastatic prostate cancer in our study.
Policy changes in recent years may also have yielded differential incentives to choose
specific therapies. Notably, the decline in Medicare reimbursement for medical castration,
which resulted from the Medicare Modernization Act, may be influential in men’s treatment
decisions.32 As new data become available, future research should extend the investigation
of the trends presented in this study into the more current period while addressing the
limitations presented earlier. Future research may also investigate whether the differences in
therapies or timing of their initiation are associated with differences in survival, although
such an investigation will be challenging, given the need for a large study population with a
richly qualitative characterization of the disease at diagnosis, the specific indication
associated with ADT initiation, and other health and clinical care factors arising through the
post-diagnostic period.
The treatment and management of prostate cancer has improved over the past decade.
Despite these advances, the disproportionate number of African-American men who did not
receive ADT for metastatic prostate cancer mirrors the racial differences in the treatment of
clinically localized prostate cancer, where African-American men disproportionately receive
nonaggressive treatment.33–37 The reasons for not treating some patients with localized
disease, such as patient preference for nonaggressive management of low-risk prostate
cancer or limited patient survival because of illness or advanced age, are not applicable to
palliative treatment of metastatic prostate cancer with ADT. Therefore, because African-
American men tend to present with more clinically aggressive prostate cancer,2,3 it would be
expected that they would be treated with ADT more, not less, than white men, and earlier,
not later. These findings suggest racial differences in treatment persist throughout the stages
of prostate cancer, and further research is warranted to identify and address those factors that
contribute to racial disparities in ADT use and time to receipt of therapy for metastatic
prostate cancer.
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Proportion of men receiving LHRH agonists, orchiectomy, or no ADT, by diagnosis year for
African-American and white men with metastatic prostate cancer, SEER-Medicare 1991–
1999.
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Probability of receipt of ADT during months following diagnosis by race, SEER-Medicare
1991–1999.
Carson et al. Page 10














Proportion of men treated with an orchiectomy or an LHRH agonist by race, among those
receiving ADT, SEER-Medicare 1991–1999.
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Age (years), n (%)
 65–69 308 (27.2) 941 (22.7)
 70–74 315 (27.8) 1,046 (25.3)
 75–79 229 (20.2) 923 (22.3)
 80+ 281 (24.8) 1,230 (29.7)
Marital status, n (%)
 Married 529 (46.7) 2,769 (66.9)
 Not married 533 (47.0) 1,204 (29.1)
 Data missing 71 (6.3) 167 (4.0)
Diagnosis year, n (%)
 1991 168 (14.8) 707 (17.1)
 1992 217 (19.2) 757 (18.3)
 1993 147 (13.0) 555 (13.4)
 1994 127 (11.2) 419 (10.1)
 1995 124 (10.9) 412 (10.0)
 1996 91 (8.0) 329 (7.9)
 1997 98 (8.6) 312 (7.5)
 1998 86 (7.6) 345 (8.3)
 1999 75 (6.6) 304 (7.3)
Months to ADT receipt,
 mean (standard deviation)
6.2 (15.7) 5.7 (15.0)
SEER site, n (%)
 Atlanta 188 (16.6) 256 (6.2)
 Connecticut 84 (7.4) 876 (21.2)
 Detroit 499 (44.0) 861 (20.8)
 Los Angeles 166 (14.7) 614 (14.8)
 San Francisco 152 (13.4) 511 (12.3)
 San Jose <11* 264 (6.4)
 Seattle-Puget Sound 35 (3.1) 758 (18.3)
Histologic grade, n (%)
 Well differentiated 36 (3.2) 114 (2.8)
 Moderately differentiated 310 (27.4) 1,309 (31.6)
 Poorly differentiated 534 (47.1) 1,785 (43.1)
 Data missing 253 (22.3) 932 (22.5)
Charlson comorbidity score, n (%)
 0 578 (51.0) 2,581 (62.3)
 1 203 (17.9) 739 (17.9)
 2 99 (8.7) 279 (6.7)

















 3+ 82 (7.2) 166 (4.0)
 Data missing 171 (15.1) 375 (9.1)
Census tract % high-school education, n (%)
 Lowest tertile: 24%–79% 777 (68.6) 686 (16.6)
 Middle tertile: 80%–89% 184 (16.2) 1,166 (28.2)
 Highest tertile: 90%–100% 61 (5.4) 1,527 (36.9)
 Data missing 111 (9.8) 761 (18.4)
Census tract median household income, n (%)
 Lowest tertile:
  $7,657–40,111
792 (69.9) 662 (16.0)
 Middle tertile:
  $40,112–57,972
170 (15.0) 1,283 (31.0)
 Highest tertile:
  $57,973–200,008
60 (5.3) 1,434 (34.6)
 Data missing 111 (9.8) 761 (18.4)
*
Cell sizes less than 11 are not reported for SEER-Medicare data.
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Table 2
Characteristicsa of Study Participants With Metastatic Prostate Cancer—SEER-Medicare, 1991–1999
Characteristics n No ADT Orchiectomy LHRH Agonist
n 5,273 1,494 (28.3) 1,528 (29.0) 2,251 (42.7)
Age, n (%)
 65–69 1,249 373 (29.9) 276 (22.1) 600 (48.0)
 70–74 1,361 356 (26.2) 367 (27.0) 638 (46.9)
 75–79 1,152 295 (25.6) 377 (32.7) 480 (41.7)
 80+ 1,511 470 (31.1) 508 (33.6) 533 (35.3)
Race, n (%)
 White 4,140 1,054 (25.5) 1,238 (29.9) 1,848 (44.6)
 African American 1,133 440 (38.8) 290 (25.6) 403 (35.6)
Marital status, n (%)
 Married 3,298 850 (25.8) 964 (29.2) 1,484 (45.0)
 Not married 1,737 576 (33.2) 515 (29.6) 646 (37.2)
 Data missing 238 68 (28.6) 49 (20.6) 121 (50.8)
Diagnosis year, n (%)
 1991 875 216 (24.7) 421 (48.1) 238 (27.2)
 1992 974 264 (27.1) 358 (36.8) 352 (36.1)
 1993 702 174 (24.8) 221 (31.5) 307 (43.7)
 1994 546 145 (26.6) 150 (27.5) 251 (46.0)
 1995 536 156 (29.1) 136 (25.4) 244 (45.5)
 1996 420 145 (34.5) 89 (21.2) 186 (44.3)
 1997 410 123 (30.0) 65 (15.9) 222 (54.1)
 1998 431 160 (37.1) 50 (11.6) 221 (51.3)
 1999 379 111 (29.3) 38 (10.0) 230 (60.7)
SEER site, n (%)
 Atlanta 444 116 (26.1) 133 (30.0) 195 (43.9)
 Connecticut 960 222 (23.1) 284 (29.6) 454 (47.3)
 Detroit 1,360 454 (33.4) 383 (28.2) 523 (38.5)
 Los Angeles 780 225 (28.8) 182 (23.3) 373 (47.8)
 San Francisco 663 201 (30.3) 201 (30.3) 261 (39.4)
 San Jose 273 57 (20.9) 91 (33.3) 125 (45.8)
 Seattle-Puget Sound 793 219 (27.6) 254 (32.0) 320 (40.4)
Histologic grade, n (%)
 Well differentiated 150 38 (25.3) 41 (27.3) 71 (47.3)
 Moderately differentiated 1,619 447 (27.6) 438 (27.1) 734 (45.3)
 Poorly differentiated 2,319 513 (22.1) 781 (33.7) 1,025 (44.2)
 Data missing 1,185 496 (41.9) 268 (22.6) 421 (35.5)
Charlson comorbidity score, n (%)
 0 3,159 706 (22.3) 957 (30.3) 1,496 (47.4)
 1 942 251 (26.6) 313 (33.2) 378 (40.1)
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Characteristics n No ADT Orchiectomy LHRH Agonist
 2 378 124 (32.8) 100 (26.5) 154 (40.7)
 3+ 248 94 (37.9) 72 (29.0) 82 (33.1)
 Data missing 546 319 (58.4) 86 (15.8) 141 (25.8)
Census tract % high-school education, n (%)
 Lowest tertile: 24%–79% 1,463 502 (34.3) 415 (28.4) 546 (37.3)
 Middle tertile: 80%–89% 1,350 359 (26.6) 426 (31.6) 565 (41.9)
 Highest tertile: 90%–100% 1,588 384 (24.2) 433 (27.3) 771 (48.6)
 Data missing 872 249 (28.6) 254 (29.1) 369 (42.3)
Census tract median household income, n (%)
 Lowest tertile: $7,657–40,111 1,454 505 (34.7) 410 (28.2) 539 (37.1)
 Middle tertile: $40,112–57,972 1,453 388 (26.7) 458 (31.5) 607 (41.8)
 Highest tertile: $57,973–200,008 1,494 352 (23.6) 406 (27.2) 736 (49.3)
 Data missing 872 249 (28.6) 254 (29.1) 369 (42.3)
a
All pairwise comparisons of percentages for each non-missing level were statistically significant (P < 0.05) except for orchiectomy vs. no ADT
for San Francisco, using Tukey’s multiple comparison test.
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Table 3
Mean Time Ratios and 95% CI for Time to Receipt of ADT From Multivariate Accelerated Failure Time
Model—SEER-Medicare, 1991–1999
Ratio of Time to Receipt (95% CI)
Characteristics Orchiectomy vs. No ADT LHRH vs. No ADT LHRH vs. Orchiectomy
Race
 White 1.00 1.00 1.00
 African American 1.50 (1.03, 2.17) 1.42 (1.06, 1.89) 1.19 (0.97, 1.45)
Age (years)
 65–69 1.00 1.00 1.00
 70–74 0.52 (0.34, 0.79) 0.80 (0.61, 1.05) 0.95 (0.78, 1.15)
 75–79 0.23 (0.15, 0.35) 0.54 (0.40, 0.73) 0.78 (0.64, 0.96)
 80+ 0.13 (0.09, 0.20) 0.47 (0.34, 0.64) 0.82 (0.67, 1.01)
Marital status
 Married 1.00 1.00 1.00
 Unmarried 0.83 (0.61, 1.13) 1.01 (0.80, 1.28) 0.94 (0.80, 1.10)
Diagnosis year
 1991 0.07 (0.03, 0.16) 2.78 (1.75, 4.41) 3.74 (2.73, 5.14)
 1992 0.11 (0.05, 0.24) 1.89 (1.25, 2.88) 2.57 (1.93, 3.43)
 1993 0.13 (0.06, 0.29) 1.44 (0.93, 2.22) 1.91 (1.41, 2.59)
 1994 0.13 (0.05, 0.29) 1.28 (0.81, 2.04) 1.62 (1.18, 2.23)
 1995 0.17 (0.07, 0.39) 1.17 (0.74, 1.85) 1.25 (0.91, 1.72)
 1996 0.30 (0.12, 0.76) 1.38 (0.85, 2.25) 1.03 (0.73, 1.47)
 1997 0.23 (0.09, 0.59) 0.69 (0.43, 1.12) 0.88 (0.63, 1.23)
 1998 1.42 (0.55, 3.70) 1.64 (1.04, 2.60) 1.03 (0.74, 1.45)
 1999 1.00 1.00 1.00
SEER site
 Atlanta 1.20 (0.66, 2.19) 0.79 (0.50, 1.25) 0.78 (0.57, 1.07)
 Detroit 2.18 (1.38, 3.43) 1.43 (1.00, 2.04) 0.99 (0.78, 1.26)
 Connecticut 0.76 (0.46, 1.25) 0.49 (0.34, 0.71) 0.58 (0.45, 0.74)
 Los Angeles 1.17 (0.69, 1.99) 0.74 (0.51, 1.08) 0.66 (0.51, 0.85)
 San Francisco 1.26 (0.74, 2.14) 0.82 (0.54, 1.24) 0.73 (0.55, 0.97)
 San Jose 1.47 (0.74, 2.89) 0.94 (0.55, 1.61) 0.98 (0.69, 1.39)
 Seattle-Puget Sound 1.00 1.00 1.00
Histologic grade
 Well differentiated 1.00 1.00 1.00
 Moderately differentiated 0.76 (0.36, 1.64) 1.08 (0.62, 1.88) 1.17 (0.79, 1.73)
 Poorly differentiated 0.26 (0.12, 0.54) 0.48 (0.28, 0.83) 0.91 (0.62, 1.34)
Comorbidity score
 0 1.00 1.00 1.00
 1 0.66 (0.46, 0.94) 0.97 (0.73, 1.29) 1.03 (0.85, 1.24)
 2 0.71 (0.40, 1.27) 0.72 (0.47, 1.11) 0.79 (0.60, 1.06)
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Ratio of Time to Receipt (95% CI)
Characteristics Orchiectomy vs. No ADT LHRH vs. No ADT LHRH vs. Orchiectomy
 3+ 0.73 (0.38, 1.40) 1.06 (0.62, 1.80) 0.82 (0.56, 1.20)
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